TSX:BCT - Post Discussion
Post by
LondonInvest on Mar 25, 2022 7:39am
Potential for this company - 10x ($100+/share)
I have bought BCTX aggressively because it is a very undervalued company for it's potential value in its research. I have been trying to calculate what potential value is if their tech continues to be confirmed and it can be applied to lung, prostate, renal and other cancers in addition to breast cancer.
A 10x increase in price to a market cap of $1.5 bn seems too cheap. A 50x increase gets to $7.5 billion. This seems the right value and where Moderna was pre-COVID.
Thinking out loud. They have enough cash on hand to get 2-3 years research. This company will not be public and/or it will have a partnership before that time. Based on appreciation potenial above it would get to a share price around $90-$400 per share. I really don't think a valuation over $100 is unreasonable and multiples is possible if results continue to come in showing massive application and potential BCTX research has.
Happy to hear other thoughts on this and other biotech comparisons that could be made.
Be the first to comment on this post